Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia. ReFacto is a recombinant factor VIII product formulated without human serum albumin in its final formulation.

Compared with the previous method for reconstituting ReFacto, the R2 kit provides a faster and simpler infusion process. The R2 kit contains a syringe prefilled with diluent, a vial adapter, and a single-use vial of ReFacto containing either 250, 500, 1000, or 2000 IUs. The adapter is placed on the vial of ReFacto, and the adapter and prefilled syringe allow ReFacto to be reconstituted without the risk of needle exposure. The R2 kit is provided in a smaller package and has fewer components, reducing required storage space.

“The ReFacto R2 kit, with its simpler and faster infusion process and fewer components will enable ReFacto patients to spend less time infusing and more time living their lives,” said Dr. Gary L. Stiles, Executive Vice President and Chief Medical Officer of Wyeth Pharmaceuticals.

Wyeth anticipates that the ReFacto R2 Kit – R2 stands for Rapid Reconstitution -- will be available in the 4th quarter of 2004.

“At Wyeth, we are committed to the hemophilia community, and we continue to look for ways to improve lives through innovation. The ReFacto R2 Kit is the latest example of our commitment to providing tools that allow patients and their families to more conveniently incorporate hemophilia treatment into their everyday lives,” said Dr. Stiles.

About Hemophilia

Hemophilia A is a rare, inherited blood clotting disorder for which there is no cure. People with hemophilia A are deficient in the key protein (factor VIII) that is vital in the clotting cascade to prevent bleeding. Hemophilia A is characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. In the United States, between 15,000 and 17,000 people have hemophilia A.

About ReFacto

ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical and short-term routine prophylaxis in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown. As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions. The remote possibility exists for hypersensitivity to non-human mammalian proteins. Please see full Prescribing Information at http://www.hemophiliavillage.com.

About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company’s periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.